Maravai LifeSciences Holdings, Inc.

NasdaqGS:MRVI Rapport sur les actions

Capitalisation boursière : US$1.2b

Maravai LifeSciences Holdings Croissance future

Future contrôle des critères 0/6

Maravai LifeSciences Holdings devrait augmenter ses bénéfices et son chiffre d'affaires de 84.7% et de 6.7% par an respectivement. Le BPA devrait croître de de 86.7% par an. Le rendement des capitaux propres devrait être -4.1% dans 3 ans.

Informations clés

84.7%

Taux de croissance des bénéfices

86.7%

Taux de croissance du BPA

Life Sciences croissance des bénéfices18.4%
Taux de croissance des recettes6.7%
Rendement futur des capitaux propres-4.1%
Couverture par les analystes

Good

Dernière mise à jour14 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Slammed 37% Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Screens Well Here But There Might Be A Catch

Nov 11
Slammed 37% Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Screens Well Here But There Might Be A Catch

Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?

Oct 15
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors

Jul 18
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors

Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?

Jul 15
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?

Maravai: Embedded Expectations Remain Too High Considering Economic Calculus

Jul 12

RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One

Jun 12

Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

May 14
Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Apr 07
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Feb 28
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Dec 19
Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Aug 14
Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Feb 28
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 01
Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Maravai Lifesciences temporarily reinstates Carl Hull as CEO

Oct 19

Maravai LifeSciences appoints former Danaher executive as CEO

Oct 03

Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M

Aug 04

Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jun 27
Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 29
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:MRVI - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026304-2593211
12/31/2025270-38-13215
12/31/2024261-120-953115
9/30/2024277-225-1230N/A
6/30/2024279-132-1731N/A
3/31/2024274-131-3133N/A
12/31/2023289-11961126N/A
9/30/202342025163218N/A
6/30/202354475268314N/A
3/31/2023718153437459N/A
12/31/2022883220519536N/A
9/30/2022907238479495N/A
6/30/2022920248479491N/A
3/31/2022895226478493N/A
12/31/2021799182354369N/A
9/30/2021669150371389N/A
6/30/2021552127308335N/A
3/31/202138178155181N/A
12/31/202028477127152N/A
12/31/2019143-8724N/A
12/31/2018124-18-40N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MRVI devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: MRVI devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: MRVI devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de MRVI ( 6.7% par an) devrait croître plus lentement que le marché de US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de MRVI ( 6.7% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: MRVI devrait être non rentable dans 3 ans.


Découvrir les entreprises en croissance